The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells

AIMS: To understand the mechanism by which imeglimin (a new oral hypoglycemic agent whose phase 3 development program in Japan has now been completed) decreases hepatic glucose production. MATERIALS AND METHODS: We compared the effect of imeglimin and metformin on glucose production, ATP/ADP ratio,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Endocrinol Diabetes Metab
Autors principals: Vial, Guillaume, Lamarche, Frédéric, Cottet‐Rousselle, Cécile, Hallakou‐Bozec, Sophie, Borel, Anne‐Laure, Fontaine, Eric
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2021
Matèries:
Original Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8029524/
https://ncbi.nlm.nih.gov/pubmed/33855213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/edm2.211
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars